Physcion
CAS 521-61-9
Physcion (CAS 521-61-9) is a pharmaceutical compound with 6 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 98569.0520754717 nM | 53 | - |
| - | Potency | 19225.415384615386 nM | 13 | - |
| - | IC50 | 30083.333333333332 nM | 9 | - |
| - | IC50 | 17.634999999999998 ug.mL-1 | 2 | - |
| - | MIC | 170 ug.mL-1 | 2 | - |
| - | Ki | 10000 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Physcion used for in pharmaceutical contexts?
Physcion (CAS 521-61-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Physcion?
No adverse-event association or SIDER side-effect rows are rendered for Physcion in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Physcion also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for MORINDA OFFICINALIS ROOT EXTRACT with EU status "permitted".
What clinical phase is Physcion in?
No phase 1-4 clinical development badge is rendered for Physcion because the matched compound identifier rows do not contain a max-phase value.